Lupus Anticoagulant and Anticardiolipin Antibodies in Serum of Patients Treated With Risperidone
J Clin Psychiatry 2009;70(5):769-771 [letter]
© Copyright 2014 Physicians Postgraduate Press, Inc.
Purchase This PDF for $40.00
If you are not a paid subscriber, you may purchase the PDF.
(You'll need the free Adobe Acrobat Reader.)
Receive immediate full-text access to JCP. You can subscribe to JCP online-only ($86) or print + online ($156 individual).
With your subscription, receive a free PDF collection of the NCDEU Festschrift articles. Hurry! This offer ends December 31, 2011.
If you are a paid subscriber to JCP and do not yet have a username and password, activate your subscription now.
As a paid subscriber who has activated your subscription, you have access to the HTML and PDF versions of this item.
Click here to login.
Did you forget your password?
Still can't log in? Contact the Circulation Department at 1-800-489-1001 x4 or send email
Letter to the Editor
Sir: In recent years, several studies reported an increased
rate of cerebrovascular events in patients treated with risperidone.
In April 2005, the U.S. Food and Drug Administration issued
a health advisory warning concerning an increased risk of
death among patients with dementia who were treated with
atypical antipsychotic agents.
Risperidone is a second-generation antipsychotic agent that
reportedly increases the blood level of glucose and alters
changes in lipid profiles.